Role of Inferior Vena Cava Filter Retrieval in Patients on Chronic Anticoagulation Therapy

Abstract

Purpose of review Describe the role of inferior vena cava filter (IVCF) retrieval in patients on chronic anticoagulation given the overlap of these treatment options in the management of patients with venous thromboembolic disease. Recent findings Despite the increase in IVCF retrievals since the Food and Drug Administration safety communications in 2010 and 2014, retrieval rates remain low. Previous studies have shown that longer filter dwell times are associated with greater risk for filter complications and more difficulty with filter retrievals. Recent findings suggest that complications are more frequent in the first 30 days after placement. Summary The decision to retrieve an optional IVCF is individualized and requires diligent follow-up with consistent re-evaluation of the need for the indwelling IVCF, particularly in those on long-term anticoagulation therapy.

Bismuth Nanoparticle and Polyhydroxybutyrate Coatings Enhance the Radiopacity of Absorbable Inferior Vena Cava Filters for Fluoroscopy-Guided Placement and Longitudinal Computed Tomography Monitoring in Pigs

“…1 Compared with deep vein thrombosis alone, pulmonary embolism increases the risk of early death 18-fold and is an independent indicator of reduced survival for up to 3 months after onset. 2,3 Anticoagulation is the cornerstone of management but for patients with contraindications to anticoagulation, placement of inferior vena cava filters (IVCFs) is used to prevent pulmonary embolism. 4,5 Despite the utility of IVCFs, complications from prolonged dwell of the filter include filter thrombosis, strut penetration, and device fracture.…”

“…Venous thromboembolism, with an estimated 1–2 events per 1000 individuals per year, causes 60,000–100,000 deaths annually in the United States . Compared with deep vein thrombosis alone, pulmonary embolism increases the risk of early death 18-fold and is an independent indicator of reduced survival for up to 3 months after onset. , Anticoagulation is the cornerstone of management but for patients with contraindications to anticoagulation, placement of inferior vena cava filters (IVCFs) is used to prevent pulmonary embolism. , Despite the utility of IVCFs, complications from prolonged dwell of the filter include filter thrombosis, strut penetration, and device fracture. The US Food and Drug Administration conducted a quantitative decision analysis in 2014 of the literature to assess whether there was a time period during which having an IVCF in place outweighed the benefits for patients with a transient risk of pulmonary embolism.…”